Guided Therapeutics (GTHP) Gross Margin (2012 - 2025)

Guided Therapeutics (GTHP) has 14 years of Gross Margin data on file, last reported at 77.63% in Q4 2025.

• For the quarter ending Q4 2025, Gross Margin rose 27763.0% year-over-year to 77.63%; the trailing twelve-month figure through Dec 2025 stood at 74.58% (up 4600.0% YoY), and the FY2025 full-year result was 74.45%, up 4587.0% from the prior year.
• Gross Margin climbed to 77.63% in Q4 2025, from 58.33% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2021 to a low of 200.0% in Q4 2024.
• A 5-year average of 36.54% and a median of 67.09% in 2024 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin slumped 27167 bps in 2021 and soared 27763 bps in 2025, its largest moves.
• Tracing GTHP's Gross Margin over 5 years: stood at 68.33% in 2021, then jumped by 46 bps to 100.0% in 2022, then tumbled by 50 bps to 50.0% in 2023, then plunged by 500 bps to 200.0% in 2024, then surged by 139 bps to 77.63% in 2025.
• Business Quant data shows GTHP's Gross Margin at 77.63% in Q4 2025, 58.33% in Q3 2025, and 67.52% in Q2 2025.